Streptokinase for Acute Ischemic Stroke with Relationship to Time of Administration (ASK Trial) The Australian Streptokinase (ASK) trial, conducted in Australia, was a double-blinded, randomized, placebo-controlled trial to determine whether administration of 1.5 MU of streptoki-nase intravenously within 4 hr of the onset of acute ischemic stroke would reduce morbidity and mortality at 3 months, and whether outcomes would be better for those receiving therapy within 3 hr of stroke onset, as compared with those receiving it after 3 hr (19). A total of 340 patients with moderate-to-severe strokes were randomized from June 1992 to November 1994. Using the outcome measure of combined death and disability score (Barthel index < 60) 3 months after the stroke, no significant difference was seen between the two groups. This study was stopped early due to an increase in mortality in the treatment group (36.2%) versus the placebo group (20.5%). An excessive amount of symptomatic hematomas was also seen in the treated group (12.6%) versus the placebo group (2.4%; p < 01). The trial did demonstrate that patients treated in < 3 hr had better outcome and less mortality than those treated between 3 and 4 hr.

Your Heart and Nutrition

Your Heart and Nutrition

Prevention is better than a cure. Learn how to cherish your heart by taking the necessary means to keep it pumping healthily and steadily through your life.

Get My Free Ebook

Post a comment